TX-MOBIL-1/FORZA-MTRSPRT
Today, the Mobil 1 brand, the world's leading synthetic engine oil, announced its expanded collaboration with Forza Motorsport, the best-selling and most-awarded racing video game franchise, in which gamers and race fans around the world will be able to compete against professional motorsports drivers such as racing legend Tony Stewart and recent INDY NXT winner Jamie Chadwick. Beginning July 25, 2024, gamers and motorsports fans will have the unique opportunity to compete against these drivers on Maple Valley, a United States-themed, Mobil 1-branded, in-game track. Additional professional race car drivers will be announced later this year for gamers to compete against in upcoming Legend vs. Leaderboard Rival Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725776163/en/
Motorsports icons including Tony Stewart and Jamie Chadwick to race gamers in-game and on-track in Legend vs. Leaderboard Rival Events. (Graphic: Business Wire)
The collaboration continues the celebration of the Mobil 1 brand’s 50th anniversary through exclusive branded content, a chance to win incredible prizes, and the opportunity to beat iconic motorsports driver’s timed laps on the 4.81km virtual course. The Forza Motorsport collaboration marks the Mobil 1 brand’s largest campaign in the video game entertainment space and celebrates both the Mobil 1 team’s 50-year legacy and its longstanding passion for racing.
Kicking off the Legend vs. Leaderboard Rival Events is racing legend Tony Stewart, an American motorsports icon. From July 25 to August 7, 2024, gamers will have the chance to try to beat Stewart’s time on the Maple Valley virtual racetrack. Fans can also look forward to exclusive content on Mobil 1 Racing social media channels – part of a Legend vs. Leaderboard Rival Events social media series – showcasing Stewart setting his time to beat while driving a classic 1969 Ford Mustang Boss 302. New celebrity drivers will be featured in the content series throughout the remainder of 2024. Each month, a new legendary driver will take on the Maple Valley track, providing ongoing challenges, new prizes, and additional content for audiences to enjoy.
“We are thrilled to bring this iconic collaboration to life with Forza Motorsport to continue the celebration of the Mobil 1 brand's historic 50th anniversary,” said Laura Bustard, Global Brand Manager, on behalf of the Mobil 1 team. “This collaboration signifies our continued commitment to innovation and excellence in motorsports while also showcasing our passion for racing beyond a physical racetrack but increasingly in the virtual world. We are proud to have created a dynamic and immersive experience for gamers and race fans that allows us to celebrate our legacy, and we cannot wait to see fans share in the excitement by racing against a variety of professional motorsports drivers.”
Later this summer, the next Legends vs. Leaderboard Rivals Event series will take place and feature British racing driver Jamie Chadwick. From August 29 through September 11, 2024, gamers will have the opportunity to race against the rising motorsports star. Chadwick will be racing a 1967 Corvette as she invites the global Forza Motorsport audience to join her in-game for the chance to beat her timed lap.
Forza Motorsport, created by Turn 10 Studios and Xbox Game Studios, continues to be one of the premier racing games by giving players an opportunity to participate in racing events around a variety of both real and fictional tracks – including some of their favorite tracks – available in-game. As the Mobil 1 brand continues to grow within the gaming space and curate incredible experiences for driving enthusiasts, the Forza Motorsport relationship serves as a key milestone to reach new audiences and provide unique virtual automotive experiences – all while sharing its love of driving at a global level.
The Legends vs. Leaderboard Rival Events will kick off on July 25 and run through December 11, 2024 with five different events for gamers and race fans to participate in.
To stay up to date and learn more about this collaboration, visit https://promotions.mobil.com/offers/Mobil1Gaming-forza. Also, stay tuned for driver announcements and exclusive content on @Mobil1Racing on Instagram and X.
About Mobil 1
For 50 years, the Mobil 1 brand has been trusted by drivers to help keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1 products, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725776163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom